ES2190819T3 - Procedimiento de preparacion de formulaciones galenicas noveles que contienen fenobrinato, formulaciones galenicas asi obtenidas y sus aplicaciones. - Google Patents

Procedimiento de preparacion de formulaciones galenicas noveles que contienen fenobrinato, formulaciones galenicas asi obtenidas y sus aplicaciones.

Info

Publication number
ES2190819T3
ES2190819T3 ES99941732T ES99941732T ES2190819T3 ES 2190819 T3 ES2190819 T3 ES 2190819T3 ES 99941732 T ES99941732 T ES 99941732T ES 99941732 T ES99941732 T ES 99941732T ES 2190819 T3 ES2190819 T3 ES 2190819T3
Authority
ES
Spain
Prior art keywords
galenic formulations
fenofibrate
phenobrinate
procedure
applications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99941732T
Other languages
English (en)
Inventor
Claude Laruelle
Rene Gimet
Dominique Toselli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CLL Pharma SA
Original Assignee
CLL Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9530543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2190819(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CLL Pharma SA filed Critical CLL Pharma SA
Application granted granted Critical
Publication of ES2190819T3 publication Critical patent/ES2190819T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Procedimiento de preparación de una formulación galénica que comprende fenofibrato como principio activo, caracterizado porque comprende las siguientes etapas: (a) la micronización del fenofibrato; (b) la granulación del fenofibrato así micronizado en presencia de un medio líquido que comprende un agente tensioactivo, agua y un alcohol miscible con agua; y (c) el secado del granulado así obtenido.
ES99941732T 1998-09-17 1999-09-10 Procedimiento de preparacion de formulaciones galenicas noveles que contienen fenobrinato, formulaciones galenicas asi obtenidas y sus aplicaciones. Expired - Lifetime ES2190819T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9811611A FR2783421B1 (fr) 1998-09-17 1998-09-17 Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications

Publications (1)

Publication Number Publication Date
ES2190819T3 true ES2190819T3 (es) 2003-08-16

Family

ID=9530543

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99941732T Expired - Lifetime ES2190819T3 (es) 1998-09-17 1999-09-10 Procedimiento de preparacion de formulaciones galenicas noveles que contienen fenobrinato, formulaciones galenicas asi obtenidas y sus aplicaciones.

Country Status (16)

Country Link
EP (1) EP1112064B1 (es)
JP (1) JP2002526438A (es)
KR (1) KR100712032B1 (es)
AT (1) ATE230979T1 (es)
AU (1) AU5523599A (es)
BR (1) BR9913782A (es)
CA (1) CA2342742A1 (es)
CZ (1) CZ298634B6 (es)
DE (1) DE69904954D1 (es)
ES (1) ES2190819T3 (es)
FR (1) FR2783421B1 (es)
MX (1) MXPA01002801A (es)
PL (1) PL194847B1 (es)
SK (1) SK284950B6 (es)
WO (1) WO2000016749A1 (es)
ZA (1) ZA200101894B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
FR2819720B1 (fr) 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
GB0119480D0 (en) 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
AU2003263480A1 (en) * 2002-09-24 2004-04-19 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of fenofibrate having high bioavailability
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
EP2842547A1 (en) 2013-08-27 2015-03-04 Freund Pharmatec Ltd. Improved fenofibrate compositions
EP2878311A1 (en) 2013-11-27 2015-06-03 Freund Pharmatec Ltd. Solubility Enhancement for Hydrophobic Drugs
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
CN104352466A (zh) * 2014-11-17 2015-02-18 辰欣药业股份有限公司 一种非诺贝特组合物及其制剂
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
DE19608750A1 (de) * 1996-03-06 1997-09-11 Durachemie Gmbh & Co Kg Verfahren zur Herstellung von Fenofibrat-Präparaten
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation

Also Published As

Publication number Publication date
SK284950B6 (sk) 2006-03-02
BR9913782A (pt) 2001-06-05
AU5523599A (en) 2000-04-10
ZA200101894B (en) 2003-01-07
KR100712032B1 (ko) 2007-04-27
PL194847B1 (pl) 2007-07-31
PL346714A1 (en) 2002-02-25
CA2342742A1 (fr) 2000-03-30
FR2783421A1 (fr) 2000-03-24
MXPA01002801A (es) 2002-04-08
ATE230979T1 (de) 2003-02-15
EP1112064B1 (fr) 2003-01-15
SK3552001A3 (en) 2001-09-11
JP2002526438A (ja) 2002-08-20
EP1112064A1 (fr) 2001-07-04
DE69904954D1 (de) 2003-02-20
KR20010075182A (ko) 2001-08-09
WO2000016749A1 (fr) 2000-03-30
CZ298634B6 (cs) 2007-11-28
FR2783421B1 (fr) 2000-11-24
CZ2001979A3 (cs) 2001-08-15

Similar Documents

Publication Publication Date Title
ES2190819T3 (es) Procedimiento de preparacion de formulaciones galenicas noveles que contienen fenobrinato, formulaciones galenicas asi obtenidas y sus aplicaciones.
DK653688A (da) Stabiliserede laegemiddelaktive forbindelser, fremgangsmaade til deres frmstilling samt stabile laegemiddelpraeparater
PT93170A (pt) Processo para a preparacao de dispositivos distribuidores nomeadamente de capsulas contendo um ingrediente activo
GB2085880B (en) 1-carboxyalkanoylindoline-2-carboxylic acids process for their manufacture pharmaceutical preparations containing thhese compounds and their therapeutic application
NO20005431D0 (no) Gelérbare farmasøytiske preparater
SE8700498D0 (sv) Novel pharmaceologically active compounds
KR910014120A (ko) 피모벤단의 경구용 약제학적 제제
BR0009759A (pt) Formulação agroquìmica na forma sólida granular, e, métodos para preparação de uma mistura de pulverização e para tratamento de plantas
PT93168A (pt) Processo para a preparacao de dispositivos distribuidores nomeadamente de capsulas contendo ingredientes activos
FI810511L (fi) Kefalosporinderivat och foerfarande foer framstaellning av dem
HK1068282A1 (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for usein treatment of ulcerative colitis and crohn's di sease
ITMI931326A1 (it) Composizione farmaceutica liquida per uso orale contenente acido 2-(4-isobutilfenil) propionico
ES2057168T3 (es) Material compuesto apto para dilatarse en presencia de agua, soportes utilizables para su fabricacion y sus utilizaciones.
PT1275377E (pt) Granulados contendo substancias lipossoluveis e sua preparacao
FI65616B (fi) Foerfarande foer framstaellning av farmaceutiskt anvaendbara 1-oxadiazolylfenoxi-3-(4-fenylpiperazinyl)-propanol-2-derivat
AR006565A1 (es) Suspensiones acuosas de beta-ciflutrina
KR970704447A (ko) 푸시드산 정제의 제조방법(Preparation of fusidic acid tablets)
DK401683A (da) Substituerede benzensulfonsyreestere, fremgangsmaade til deres fremstilling og deres anvendelse som laegemidler
JPS5517326A (en) Creamy drug for external use, and its preparation
JPS55129220A (en) Composition for solid preparation containing hardly soluble medicinal component having rapid action and high bioavailability
ES2127305T3 (es) Una forma farmaceutica para la administracion rectal de compuestos farmacologicamente activos.
JPS55160715A (en) Tablet having improved disintegrating property
TH6020B (th) สูตรผสมเมนาไดโอนไบซัลโฟท์ที่ได้ทำให้เสถียร และการเตรียมสูตรผสมเหล่านี้
TH5974A (th) สูตรผสมเมนาไดโอนไบซัลโฟท์ที่ได้ทำให้เสถียร และการเตรียมสูตรผสมเหล่านี้
IT8620737A0 (it) Composizioni farmaceutiche contenenti levodopa metil estere, loro procedimento di preparazione e relative applicazioni terapeutiche.